Pazopanib for the first-line treatment of advanced renal cell carcinoma

  • Technology appraisal guidance
  • TA215
  • Published: 
  • Last updated: 
Download guidance (PDF)

Update information

August 2013: Part B of the patient access scheme was removed.

April 2017: The company changed from GlaxoSmithKline to Novartis. Contact details for the patient access scheme updated.

ISBN: 978-1-4731-2483-7